克唑替尼是针对间变淋巴瘤激酶(anaplastic lymphoma kinase, ALK)融合基因、ROS-1重排等靶点的药物。本文观察克唑替尼治疗ALK/ROS1重排阳性的晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)的近远期疗效。. Here, ROS1 is linked to non-small cell lung carcinoma.